The metastatic cancer drug developer has secured $60.8m from investors including Celgene and the WuXi AppTec-backed 6 Dimensions Capital.

US-based oncology company HiberCell has officially launched with $60.8m of series A funding from investors including pharmaceutical firm Celgene and 6 Dimensions Capital, the strategic investment vehicle co-founded by drug producer WuXi AppTec. The series A round was led by venture capital firm Arch Venture Partners and also featured municipal investment vehicle NYC Life Sciences…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.